Abstract.
Although the contribution of B-cell derived autoreactive antibodies to rheumatoid arthritis (RA) has been studied extensively, the autoantibody-independent roles of B cells in the progression of the disease is not well-defined. Here we present the first comprehensive transcriptome profile of human autoreactive B cells in an autoimmune disease by performing RNA-sequencing of citrulline-specific B cells from RA patients.
In order to facilitate a comprehensive understanding of the profile of these citrullinespecific (RA-CCP POS ) B cells, we performed comparative analyses to both citrulline- 
Introduction.
RA is an autoimmune disease characterized by swelling of the synovial membrane with the robust infiltration of cells of both the innate and adaptive immune system: B cells, T cells, macrophages, dendritic cells, neutrophils and mast cells 1 . The identification of citrullination, the post-translational modification of arginine residues to citrulline in proteins, catalyzed by the enzymes peptidyl arginine deaminases (PADs), as one of the key factors mediating the breach in tolerance and eliciting anti-citrullinated protein antibody (ACPA) responses, has been a major milestone for RA 2, 3 . The appearance of ACPA in circulation precedes the onset of clinical disease, and ACPA positivity has a sensitivity of 60-70%, and a specificity of greater than 90%, for the diagnosis of RA 2 .
ACPA have shown to trigger human immune effector functions including activation of the complement system and the ability to engage activating Fcγ receptors 4 . Lastly, it has been demonstrated that ACPA can catalyze bone erosion commonly seen in RA patients 5 .
Although the indispensable role of B cells in autoantibody production is well recognized, their autoantibody-independent contributions are not as well-defined.
Systemic depletion of B cells using rituximab that targets B cells expressing human
CD20, a phenotypic cell surface marker, has been shown to be effective clinically for the treatment of a subset of RA patients 6 . While studies have supported the idea that patients with higher autoantibody titers are likely to respond to rituximab 7, 8 , the clinical efficacy of rituximab treatment is not necessarily correlated with a decrease in autoantibody titers 9 . This, in turn, implies a more expanded role for B cells in autoimmune pathogenicity beyond antibody production. Preclinical and clinical data have suggested many different functions of B cells in RA including a role as antigen presenting cells (APCs) that can process and present peptides enabling T-cell activation and proliferation 10, 11 ; direct secretion of pro-inflammatory cytokines like tumor necrosis factor (TNF) and interleukin-6 (IL-6) 12, 13, 14 ; supporting the organization of tertiary lymphoid tissues within the inflamed synovium 10, 15, 16 ; and impacting bone homeostasis through the secretion of receptor activator of nuclear factor kappa-B ligand (RANKL) 17, 18 . Despite these efforts, a direct interrogation of the roles of the autoreactive B cell compartment, and how they differ from other B cells from the same donor or from B cells from healthy individuals, has not been accomplished.
One of the major challenges in profiling autoreactive B cells within humans is the low frequency of these cells in peripheral blood (< 0.1 % of all B cells in circulation) 19 .
We Figure 1A) were sorted in 96 well plates and grown in vitro for 14 days as described previously 19 . The purity of our sorting strategy was validated by testing the supernatants after in vitro culture, which confirmed that only the immunoglobulins secreted in B- identified. The epidermal growth factor ligand, amphiregulin (AREG) was identified as the transcript with the largest change in expression ( Figure 2B ). By classifying these same DEGs into the Gene Ontology (GO) categories, we grouped them as being related to B-cell activation, genes related to inflammation, and transcription factors. We observed differences in the expression of genes related to B-cell activation ( Figure 2C) with increased expression of kinases like phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3KCA) 24 and mitogen-activated protein kinases (MAPK7/MAPK8) known to cause autoimmunity under deregulated activation 25, 26, 27 .
In addition, several genes related to inflammation including signaling molecules like TNFAIP3 28 and IL6ST 29 , and T-cell recruiting chemokine-like CCL5 30 and chemokine receptor CXCR4 31 were upregulated in RA-CCP POS B cells ( Figure 2D) . Figure 2E ).
We also sought to determine if there was a B-cell specific change in expression of genes known to be high-risk loci in RA, documented through large-scale genetic efforts 38, 39 .
Out of the known RA-specific loci, 9 genes were also identified as DEGs (SH2B3, 40, 41 ; the bone morphogenetic proteins (BMP2 and BMP5) 42 ; and the peptidyl arginine deaminase citrullinating enzymes (PADI2 and PADI6) 43 [ Figure 2F ].
Additionally, several immune-related transcripts like the inflammasome-associated protein NLRP7 44 Our ELISA results showed that the levels of AREG were significantly higher in RA as compared to osteoarthritis (OA) patients, wherein only one patient's SF tested positive for AREG ( Figure 5F ).
Amphiregulin promotes migration and proliferation of fibroblast-like synoviocytes (FLS) in vitro.
One of the hallmarks of RA pathogenesis is the activation of the FLS, which is characterized by a tumor-like aggressive phenotype within the joints 53 . We tested the ability of AREG to increase the invasiveness of human RA-FLS and observed that AREG promoted the increased migration of FLS in wound healing assays, in comparison to IL15 or controls ( Figure 6A, B) . We confirmed the expression of EGFR on RA-FLS, suggesting that the increased invasiveness is likely due to increased AREG-EGFR signaling ( Figure 6C ). By contrast, however, a lack of RA-FLS migration in the presence of IL15 could be attributed to the low surface expression of its cognate receptor IL15Rα (data not shown). We also observed that RA-FLS proliferate more in the presence of AREG in comparison to controls ( Figure 6D ) or IL15 (data not shown). Taken together, our results thus indicate that high-levels of AREG in RA patient's blood and SF could be responsible for an aggressive phenotype of FLSs in these patients.
Functional synergy between AREG and ACPA in mediating osteoclastogenesis.
The role of AREG in promoting osteolytic activity has been detailed as one of the mediators of bone metastases in breast cancers 54 . Independently, the role of ACPA in enabling osteoclast differentiation has been described in RA 5 . We thus interrogated the functional synergy between these molecules in mediating osteoclastogenesis. First, we purified the ACPA antibodies by binding to a CCP-functionalized column ( Figure 6E) .
Next, we evaluated the ability of each of these molecules either by themselves or in combination to promote the differentiation of multi-nucleated Tartrate One of the novel observation of our study is the abundance of cAMP-mediated pathways within the RA-CCP POS B cell populations. cAMP is a vital secondary messenger that plays an essential role in cellular response to many hormones, GPCRs and growth factor receptors 72 . The intracellular concentrations of cAMP are determined by the activity of two opposing enzyme families, the adenylyl cyclases (AC) and cyclic nucleotide phosphodiesterases (PDEs). The best-characterized effector of cAMP is protein kinase A (PKA) that phosphorylates a large number of cytosolic and nuclear proteins 73 .
Transcripts of PKA are directly regulated by the phosphorylation of the transcription factors cAMP-response element-binding protein (CREB), a cAMP-responsive modulator (CREM), and ATF1. It is well-documented that CREB is activated downstream of BCR signaling, and plays important roles in B cell survival and function 74 . The increased signaling through the BCR of autoreactive B cells might provide one explanation for the increase in cAMP signaling pathways documented here.
The synthetic DMARD methotrexate inhibits the enzyme dihydrofolate reductase and related enzymes, ultimately leading to the release of adenosine into the extracellular environment 75 . This, in turn, leads to increased cAMP levels by acting through the adenosine receptors, and since all our RA-CCP POS B cells were isolated from RA patients that had undergone methotrexate therapy, it is plausible that the increased cAMP signaling might be linked to therapy. Despite this, the specific increase of cAMP within the RA-CCP POS B cells, and the identification of PDE4 as a DEG suggests that inhibition of PDE4 could be explored as a potential mechanism to induce apoptosis within RA-CCP POS B cells. 48 , and AREG has also been associated with the pathogenesis of other autoimmune diseases like psoriasis 77 . Indeed, mouse models of psoriasis display synovitis and treatment with mAbs targeting AREG alleviates inflammation 78 .
The induction of AREG expression is governed by the cytokines TGFβ, TNFα, and Furthermore, as our data illustrates, AREG can directly promote the proliferation and invasiveness of FLS. As outlined by elegant studies in breast cancer metastasis models, AREG is also known to increase the differentiation and activity of osteoclasts from PBMCs in the presence of RANKL and M-CSF 54 , both of which are abundantly available in the synovial compartment of RA patients 80, 81 . Our in vitro data further advances the ability of AREG to act in concert with ACPA to enhance the differentiation of osteoclasts from blood monocytes. We thus propose an integrated model for the many different impacts of RA-CCP POS B cells in RA based on both our data and on the multi-functional roles of AREG in other disease models (Figure 7) .
Through this study, we are reporting for the first time a comprehensive transcriptome profile of RA-CCP POS B cells in RA. To the best of our knowledge, this is also the first report on whole transcriptome profiling of antigen-specific B cells in any autoimmune disorder. Our results portray B cells as not merely autoantibody producers but as a source of diverse molecules which can influence proliferation, differentiation, and activation of other pathogenic cells types. We anticipate that these data will serve as a foundational data set for investigating multiple hypotheses on the roles of B cells in RA and other autoimmune disorders, and enable drug discovery and validation based on the biology of RA-CCP POS B cells in RA.
We also recognize that while our report represents an important first step, further studies are required to gain a much deeper understanding of autoreactive B cells in autoimmune biology. Since our studies profiled CCP reactive B cells ex vivo from treated patients, it is not clear how treatment can impact the profiles described here. For this reason, it would be ideal to study new onset treatment naïve patients and perform RNA-seq on B cell isolated from these patients. At the other end of the spectrum, since
RA is an inflammatory disorder, and since the synovial compartment is a primary region of disease activity and pathology, it will be interesting to profile the autoreactive B cells isolated directly from the synovial mononuclear cells of advanced RA patients.
Nonetheless, with the aid of the ex vivo sorting method that we have utilized, these questions can be addressed with careful selection of the appropriate patient cohorts.
Similarly, the relationships between IL15, sIL15Ra, and AREG within the synovial compartment, and how they influence the expression and secretion of each other and other signaling cascades, needs better definition.
Material and methods:
Patients. Blood (15 ml) was aspirated in heparin vacutainer tubes (BD Biosciences) from RA patients after informed consent under IRB approved protocols at BCM, UAB and UH. Patient information is summarized in Table 1 . All RA patients met 1987 ARA (now ACR) classification criteria for RA 82 . Bioinformatic pathway and gene discovery. Initial quality control of the sequencing data was performed by using Cutadapt to remove the adapter sequences from the 3' end, followed by trimming of the first 12 bases of all reads at 5' end to address the nonuniform distribution caused either by biased selection of reads or contamination of other sequences. Reads shorter than 20bp were then dropped to avoid potential mapping to multiple locations on the reference genome. After performing the quality control steps, transcripts were aligned to the human reference genome UCSC hg19 using TopHat2.
Flow-sorting of
The mapped genes were annotated using R package "GenomicAlignments" and gene annotation information in R package "TxDb.Hsapiens.UCSC.hg19.knownGene".
Thereafter, differentially expressed genes (DEGs) were identified using DEseq2 tool that tests for differential gene expression based on a model using the negative binomial distribution. The differentially expressed pathways were identified by the "GAGE" package using the gene sets downloaded from the "Molecular Signature Database" of the Broad Institute and also by using the Gene Set Enrichment Analysis (GSEA)
software.
Measurement of AREG in RA patient's synovial fluid (SF).
The levels of AREG in patient's SF were measured using the commercially available kit (R&D systems). A total of thirty-two RA and eight osteoarthritis (OA) patient's SF was diluted 1:1 in assay diluent and was subjected to ELISA for the detection of AREG.
Somamer assays. Serum was assayed using the standard protocol for the SOMAscan assay (Somalogic Inc.) targeting 1,310 specific human proteins. All samples were diluted to 40%, 1%, and 0.005% and incubated with SOMAmers (Slow Off-rate Modified Aptamers) for 3.5 hours at 28°C. The SOMAmers are conjugated to beads by a photocleavable linker and to a fluorophore that is used for final detection. After a series of washes with an assay buffer of physiological pH and salt to remove nonspecific binding, the remaining bound proteins were tagged using an NHS-biotin reagent. The aptamer-protein complexes were photocleaved from the beads by UV at a peak wavelength of 365nm and attached to streptavidin-coated magnetic beads. Using a high pH denaturing wash with a chaotropic buffer containing 12 SOMAmer hybridization controls, the SOMAmers bound to their cognate proteins were eluted and quantified using a custom DNA microarray and SureScan Microarray Scanner (Agilent Technologies). Raw data was sent to Somalogic to remove within-run hybridization variation and perform median normalization across samples to remove assay biases.
The 40% dilutions of two RA samples were removed from analysis due to precipitates in the serum and all samples passed Somalogic's quality control guidelines. R's stats package was used for group statistics and normalization. 
